Scantox now licensed the PS19 transgenic mouse from the University of Pennsylvania, USA (JAX 008169; Yoshiyama et al., 2007). The mouse expresses the T34 isoform and 4 microtubule binding repeats (1N4R) of the tau protein with P301S mutation under the regulatory control of the murine prion promoter (Prnp). PS19 mice are a popular model to study tau aggregation, tauopathy and other symptoms of Alzheimer`s disease.
Animals present the following phenotype:
- Neuronal accumulation of phosphorylated tau and paired helical filaments (PHF) in different brain regions at 6 months (Yoshiyama et al., 2007)
- Cerebral atrophy and neuron loss at 12 months (Yoshiyama et al., 2007)
- Neuroinflammation observed as activated microglia and astrocytosis at 6 months and older (Yoshiyama et al., 2007; Lopez-Gonzalez et al., 2015)
- Muscle weakness and neurogenic muscular atrophy at 3 months (Yoshiyama et al., 2007)
- Reduced anxiety at 9 months (Briggs et al., 2017)
- Learning and memory deficits at 9 months (Briggs et al., 2017)
- Reduced survival (Yoshiyama et al., 2007)
Results from published efficacy studies show that many of these symptoms are partly reversible by different compounds:
- Survival, nueroinflammation, tau phosphorylation (Yoshiyama et al., 2007)
- Axonal dystrophy, learning and memory (Brunden et al., 2010)
- Brain atrophy, survival, nest building (DeVos et al., 2017)
The phenotype described above, relevant for AD and other neurodegenerative disorders, makes the PS19 mouse a perfect model for your drug testing.
Contact us today to get your study in the PS19 mouse model started!
Just released: Scantox’s latest scientific publication about the Niemann-Pick type 1 mouse model NPC1-/-
Hepatic and neuronal phenotype of NPC1−/− mice
March 26-31 2019
Meet us at the 14th International Conference on Alzheimer´s & Parkinson´s Diseases in Lisbon, Portugal
Our team will attend the AD/PD 2019 and are pleased to meet you at our booth # 28.
Additionally, our scientists are presenting our newest research results in oral and poster presentations:
Oral Presentation:
Wednesday, March 27th, 12:30H:
CHARACTERIZATION OF 4L/PS-NA MICE FOR ENZYME ACTIVITY, SUBSTRATE CONCENTRATIONS AS WELL AS INFLAMMATION TO MODEL GAUCHER DISEASE
Irene Schilcher, Ewald Auer, Victoria Schiffer, Tina Loeffler, Joerg Neddens, Staffan Schmidt, Jan Kehr, Birgit Hutter-Paier
Poster plus 5 minute talks:
Saturday, March 30th:
09:20H: # 395: TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE
Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier
10:00H: # 399: UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS
Magdalena Temmel, Meritxell Aguilo Garcia, Tina Loeffler, Joerg Neddens, Irati Aiestaran Zelaia, Vera Niederkofler, Stefanie Flunkert and Birgit Hutter-Paier
Poster:
# 348: INVESTIGATION OF SKIN SAMPLES OF ALPHA-SYNUCLEIN TRANSGENIC MICE LINE 61, D-LINE AND A53T
Joerg Neddens, Estibaliz Etxebarria, Victoria Krivitsch, Birgit Hutter-Paier
# 398: PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE
Magdalena Temmel, Tina Loeffler, Joerg Neddens, Irene Schilcher, Birgit Hutter-Paier
# 390: CONSTRUCTION OF A TAU-SEED INJECTION MODEL USING HTAU MICE
Shigeru Akasofu, Jane Gartlon, Malcolm Roberts, Ezat Sajedi, Rohan de Silva, Tina Loeffler, Birgit Hutter-Paier
# 707: BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS BACHD RATS
Tina Loeffler, Stephan Kurat, Adam Horvath, Stefanie Flunkert, Hoa Huu Phuc Nguyen, Robert Wronski, Birgit Hutter-Paier
